Red Blood Cells and Endothelium Derived Circulating Extracellular Vesicles in Health and Chronic Heart Failure: A Focus on Phosphatidylserine Dynamics in Vesiculation
Por:
Suades, R, Vilella-Figuerola, A, Padro, T, Mirabet, S, Badimon, L
Publicada:
1 jul 2023
Ahead of Print:
23 jul 2023
Resumen:
Circulating extracellular microvesicles (cEVs) are characterised by presenting surface antigens of parental cells. Since their biogenesis involves the translocation of phosphatidylserine (PS) from the inner to the outer leaflet of the plasma membrane, exposed PS has been considered as a recognition hallmark of cEVs. However, not all cEVs externalise PS. In this study, we have phenotypically and quantitatively characterised cEVs by flow cytometry, paying special attention to the proportions of PS in chronic heart failure patients (cHF; n = 119) and a reference non-HF group (n = 21). PS--cEVs were predominantly found in both groups. Parental markers showed differential pattern depending on the PS exposure. Endothelium-derived and connexin 43-rich cEVs were mainly PS--cEVs and significantly increased in cHF. On the contrary, platelet-derived cEVs were mostly PS+ and were increased in the non-HF group. We observed similar levels of PS+- and PS--cEVs in non-HF subjects when analysing immune cell-derived Evs, but there was a subset-specific difference in cHF patients. Indeed, those cEVs carrying CD45(+), CD29(+), CD11b(+), and CD15(+) were mainly PS+-cEVs, while those carrying CD14(+), CD3(+), and CD56(+) were mainly PS--cEVs. In conclusion, endothelial and red blood cells are stressed in cHF patients, as detected by a high shedding of cEVs. Despite PS+-cEVs and PS--cEVs representing two distinct cEV populations, their release and potential function as both biomarkers and shuttles for cell communication seem unrelated to their PS content.
Filiaciones:
Suades, R:
Res Inst Hosp Santa Creu i St Pau, IIB St Pau, Cardiovasc Program ICCC, Barcelona 08049, Spain
Inst Salud Carlos III ISCIII, Ctr Invest Biomed Red Enfermedades Cardiovasc CIBE, Madrid 28029, Spain
Vilella-Figuerola, A:
Res Inst Hosp Santa Creu i St Pau, IIB St Pau, Cardiovasc Program ICCC, Barcelona 08049, Spain
Padro, T:
Res Inst Hosp Santa Creu i St Pau, IIB St Pau, Cardiovasc Program ICCC, Barcelona 08049, Spain
Inst Salud Carlos III ISCIII, Ctr Invest Biomed Red Enfermedades Cardiovasc CIBE, Madrid 28029, Spain
Mirabet, S:
Inst Salud Carlos III ISCIII, Ctr Invest Biomed Red Enfermedades Cardiovasc CIBE, Madrid 28029, Spain
Hosp Santa Creu i St Pau, Cardiol Dept, Barcelona 08025, Spain
Badimon, L:
Res Inst Hosp Santa Creu i St Pau, IIB St Pau, Cardiovasc Program ICCC, Barcelona 08049, Spain
Inst Salud Carlos III ISCIII, Ctr Invest Biomed Red Enfermedades Cardiovasc CIBE, Madrid 28029, Spain
Univ Autonoma Barcelona UAB, Cardiovasc Res Chair, Barcelona 08193, Spain
gold, All Open Access, Gold
|